• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

丁酸梭菌对腹泻型肠易激综合征症状和粪便微生物群的影响：一项随机、双盲、安慰剂对照试验。

The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.

机构信息

Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, 250012, China.

Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan, 250012, China.

出版信息

Sci Rep. 2018 Feb 14;8(1):2964. doi: 10.1038/s41598-018-21241-z.

DOI:10.1038/s41598-018-21241-z
PMID:29445178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5813237/
Abstract

Irritable bowel syndrome (IBS) is a common disorder in gastrointestinal system and impairs the quality of life of the patients. Clostridium butyricum (CB) is a probiotics that has been used in several gastrointestinal diseases. The efficacy of CB in treating IBS is still unknown. This prospective, multi-centre, randomized, double-blind, placebo-controlled trial aimed to assess the efficacy and safety of CB in treating diarrhea-predominant IBS (IBS-D) and analyze the fecal microbiota after treatment. Two hundred patients with IBS-D were recruited and were given CB or placebo for 4 weeks. End points included change from baseline in IBS symptoms, quality of life, stool consistency and frequency. Compared with placebo, CB is effective in improving the overall IBS-D symptoms (-62.12 ± 74.00 vs. -40.74 ± 63.67, P = 0.038) as well as quality of life (7.232 ± 14.06 vs. 3.159 ± 11.73, P = 0.032) and stool frequency (-1.602 ± 1.416 vs. -1.086 ± 1.644, P = 0.035). The responder rates are found higher in CB compared with the placebo (44.76% vs. 30.53%, P = 0.042). The change in fecal microbiota was analyzed and function pathways of CB in treating IBS-D were predicted. In conclusion, CB improves overall symptoms, quality of life and stool frequency in IBS-D patients and is considered to be used as a probiotics in treating IBS-D clinically.

摘要

肠易激综合征（IBS）是一种常见的胃肠道系统疾病，会降低患者的生活质量。丁酸梭菌（CB）是一种已用于多种胃肠道疾病的益生菌。CB 治疗 IBS 的疗效尚不清楚。本前瞻性、多中心、随机、双盲、安慰剂对照试验旨在评估 CB 治疗腹泻型肠易激综合征（IBS-D）的疗效和安全性，并分析治疗后的粪便微生物群。招募了 200 名 IBS-D 患者，给予 CB 或安慰剂治疗 4 周。终点包括 IBS 症状、生活质量、粪便稠度和频率从基线的变化。与安慰剂相比，CB 有效改善了整体 IBS-D 症状（-62.12±74.00 与-40.74±63.67，P=0.038）以及生活质量（7.232±14.06 与 3.159±11.73，P=0.032）和粪便频率（-1.602±1.416 与-1.086±1.644，P=0.035）。CB 的应答率高于安慰剂（44.76%比 30.53%，P=0.042）。分析了粪便微生物群的变化，并预测了 CB 治疗 IBS-D 的功能途径。总之，CB 改善了 IBS-D 患者的整体症状、生活质量和粪便频率，被认为可在临床上用作治疗 IBS-D 的益生菌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/71fea467ec92/41598_2018_21241_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/98646f1b97ec/41598_2018_21241_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/e42cc21f1926/41598_2018_21241_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/1282ede7f090/41598_2018_21241_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/3c0f6e75c574/41598_2018_21241_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/5e5e91bcbffc/41598_2018_21241_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/71fea467ec92/41598_2018_21241_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/98646f1b97ec/41598_2018_21241_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/e42cc21f1926/41598_2018_21241_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/1282ede7f090/41598_2018_21241_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/3c0f6e75c574/41598_2018_21241_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/5e5e91bcbffc/41598_2018_21241_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d493/5813237/71fea467ec92/41598_2018_21241_Fig6_HTML.jpg

相似文献

1
The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.丁酸梭菌对腹泻型肠易激综合征症状和粪便微生物群的影响：一项随机、双盲、安慰剂对照试验。
Sci Rep. 2018 Feb 14;8(1):2964. doi: 10.1038/s41598-018-21241-z.
2
The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.多菌种益生菌混合物对腹泻型肠易激综合征症状和粪便微生物群的影响：一项随机、双盲、安慰剂对照试验。
J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1.
3
The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.双歧四联活菌片治疗腹泻型肠易激综合征的疗效：一项随机、双盲、安慰剂对照、多中心试验方案。
Trials. 2020 Jun 30;21(1):597. doi: 10.1186/s13063-020-04490-0.
4
A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.一项关于多菌株益生菌制剂（Bio-Kult®）用于治疗腹泻型肠易激综合征的随机安慰剂对照临床试验。
BMC Gastroenterol. 2018 May 25;18(1):71. doi: 10.1186/s12876-018-0788-9.
5
Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.长双歧杆菌 NCC3001 益生菌可降低抑郁评分并改变大脑活动：一项在肠易激综合征患者中的初步研究。
Gastroenterology. 2017 Aug;153(2):448-459.e8. doi: 10.1053/j.gastro.2017.05.003. Epub 2017 May 5.
6
Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.粪便微生物群移植可减轻部分以腹胀为主的肠易激综合征患者的症状：一项安慰剂对照随机试验的短期和长期结果
Gastroenterology. 2021 Jan;160(1):145-157.e8. doi: 10.1053/j.gastro.2020.07.013. Epub 2020 Jul 15.
7
Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.粪便微生物群移植治疗腹泻为主型肠易激综合征：一项双盲、随机、安慰剂对照试验。
Lancet Gastroenterol Hepatol. 2019 Sep;4(9):675-685. doi: 10.1016/S2468-1253(19)30198-0. Epub 2019 Jul 17.
8
A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.一项针对100名肠易激综合征患者的益生菌组合双盲随机对照试验。
Gastroenterol Clin Biol. 2008 Feb;32(2):147-52. doi: 10.1016/j.gcb.2007.06.001. Epub 2008 Mar 4.
9
A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.一项随机、双盲、安慰剂对照试验，旨在评估活 CECT 7347（ES1）和热处理 CECT 7347（HT-ES1）在腹泻为主型肠易激综合征患者中的安全性和疗效。
Gut Microbes. 2024 Jan-Dec;16(1):2338322. doi: 10.1080/19490976.2024.2338322. Epub 2024 Apr 17.
10
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.粪便微生物群移植改变肠易激综合征患者的肠道微生物群：一项随机、双盲、安慰剂对照研究的结果。
Gut. 2018 Dec;67(12):2107-2115. doi: 10.1136/gutjnl-2018-316434. Epub 2018 Jul 6.

引用本文的文献

1
Formation of gut microbiota and application of microecological regulators in children.儿童肠道微生物群的形成及微生态调节剂的应用
Transl Pediatr. 2025 Aug 31;14(8):2023-2041. doi: 10.21037/tp-2025-303. Epub 2025 Aug 25.
2
Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on CBM588 and W11.肠易激综合征的靶向益生菌疗法：对CBM588和W11的临床评估
Front Med (Lausanne). 2025 May 20;12:1604319. doi: 10.3389/fmed.2025.1604319. eCollection 2025.
3
Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects of CBM588 Probiotic on Gastrointestinal Symptoms, Quality of Life, and Gut Microbiota in a Prospective Real-Life Interventional Study.

本文引用的文献

1
Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation.随机双盲安慰剂对照试验研究干酵母 CNCM I-3856 对肠易激综合征的疗效：对以便秘为主的患者的腹痛和腹胀有改善作用。
United European Gastroenterol J. 2016 Jun;4(3):353-62. doi: 10.1177/2050640615602571. Epub 2015 Aug 21.
2
Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis.益生菌类型、剂量和治疗持续时间对罗马III标准诊断的肠易激综合征的影响：一项荟萃分析。
BMC Gastroenterol. 2016 Jun 13;16(1):62. doi: 10.1186/s12876-016-0470-z.
3
腹泻型肠易激综合征（IBS-D）：一项前瞻性真实生活干预研究中CBM588益生菌对胃肠道症状、生活质量和肠道微生物群的影响
Microorganisms. 2025 May 15;13(5):1139. doi: 10.3390/microorganisms13051139.
4
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.炎症性肠病中的肠道微生物群调节：从旧范式到革命性工具
Int J Mol Sci. 2025 Mar 27;26(7):3059. doi: 10.3390/ijms26073059.
5
ameliorates indomethacin-induced enteropathy by promoting MUC2 secretion via suppressing the Notch pathway.通过抑制Notch通路促进MUC2分泌来改善吲哚美辛诱导的肠病。
Front Microbiol. 2025 Mar 19;16:1509876. doi: 10.3389/fmicb.2025.1509876. eCollection 2025.
6
Complex Probiotics Ameliorate Fecal Microbiota Transplantation-Induced IBS in Mice via Gut Microbiota and Metabolite Modulation.复合益生菌通过调节肠道微生物群和代谢物改善粪便微生物群移植诱导的小鼠肠易激综合征
Nutrients. 2025 Feb 26;17(5):801. doi: 10.3390/nu17050801.
7
Effects of peroxidized lipids on intestinal morphology, antioxidant capacity and gut microbiome in piglets.过氧化脂质对仔猪肠道形态、抗氧化能力和肠道微生物群的影响。
Anim Nutr. 2024 Dec 27;20:430-443. doi: 10.1016/j.aninu.2024.11.015. eCollection 2025 Mar.
8
Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis.肠易激综合征中与健康相关生活质量结局的安慰剂反应变异性：一项基于臂的网络荟萃分析。
Qual Life Res. 2025 Jun;34(6):1553-1568. doi: 10.1007/s11136-025-03927-w. Epub 2025 Feb 25.
9
The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review.NLRP3炎性小体在肠易激综合征中的作用及调控：一项叙述性综述
Microorganisms. 2025 Jan 15;13(1):171. doi: 10.3390/microorganisms13010171.
10
Efficacy of Probiotics in the Management of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.益生菌在肠易激综合征管理中的疗效：一项系统评价与荟萃分析。
Cureus. 2024 Dec 18;16(12):e75954. doi: 10.7759/cureus.75954. eCollection 2024 Dec.
Probiotics in functional bowel disorders.
功能性肠病中的益生菌
Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):89-97. doi: 10.1016/j.bpg.2016.01.003. Epub 2016 Jan 14.
4
Human colorectal mucosal microbiota correlates with its host niche physiology revealed by endomicroscopy.内镜显微镜检查揭示人结肠黏膜微生物群与其宿主微环境生理学相关。
Sci Rep. 2016 Feb 26;6:21952. doi: 10.1038/srep21952.
5
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.肠道微生物群在肠易激综合征中的作用：新的治疗策略。
World J Gastroenterol. 2016 Feb 21;22(7):2219-41. doi: 10.3748/wjg.v22.i7.2219.
6
The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis.丁酸梭菌宫入株对溃疡性结肠炎患者预防袋炎及微生物群谱改变的作用。
Surg Today. 2016 Aug;46(8):939-49. doi: 10.1007/s00595-015-1261-9. Epub 2015 Oct 29.
7
Smad2 and Smad3 Inversely Regulate TGF-β Autoinduction in Clostridium butyricum-Activated Dendritic Cells.Smad2 和 Smad3 对丁酸梭菌激活的树突状细胞中 TGF-β 的自诱导作用呈相反调节。
Immunity. 2015 Jul 21;43(1):65-79. doi: 10.1016/j.immuni.2015.06.010. Epub 2015 Jun 30.
8
Genome sequencing of Clostridium butyricum DKU-01, isolated from infant feces.丁酸梭菌 DKU-01 基因组测序，该菌分离自婴儿粪便。
Gut Pathog. 2015 Mar 27;7:8. doi: 10.1186/s13099-015-0055-3. eCollection 2015.
9
Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome--a 12 week double-blind study.随机临床试验：液体多菌株益生菌与安慰剂在肠易激综合征中的应用——为期 12 周的双盲研究。
Aliment Pharmacol Ther. 2014 Jul;40(1):51-62. doi: 10.1111/apt.12787. Epub 2014 May 11.
10
A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice.一株丁酸梭菌诱导肠道产生白介素-10 的巨噬细胞抑制小鼠急性实验性结肠炎。
Cell Host Microbe. 2013 Jun 12;13(6):711-22. doi: 10.1016/j.chom.2013.05.013.